Sam Cooke? Reminds me of an Ozzy song on Sabotage, Sabbath's best album.
"Obsessed, obsessed, obsessed, obsessed, obsessed...
Obsessed with fantasy, possessed with my schemes
I mixed reality with pseudo-god dreams
How could this poison be
The dream of my soul
How did my fantasies take complete control, yeah?"
I'm not very good at calling tops or bottoms, but am happy anytime I can catch a fat middle.
I'm retired now. The way I look at it is that I made over 70% in less than two years. The profit amounts to more than half a year worth of living expenses. And the cash is a reality. If only we could all do that well all the time.
Doesn't matter how well run CLD is. All the other legacy coal companies are going BK. They'll get a fresh start... same name, same management, same equipment, but with no debt, perhaps with union contracts and environmental liabilities slashed too. They will be ready and able to compete on price. It's a death spiral for shareholders.
Just sold half remaining at $6.25.
BTW, I've been posting bullish here for years, ducati. But nothing wrong with taking profit.
The sales force training ended months ago. Now the salesmen have to convince doctors to prescribe it. AZN has to get Movantik on the preferred formularies and eliminate the need for prior authorization. If that happens, AZN needs to convince consumers to use it daily and not just as needed.
What would really help is a large, secondary, illegal diversion market.
The $3M Q1 sales represents stocking by pharmacies. It's not like Movantik sales fell off a cliff in Q2. On the other hand, $1M Q2 sales is quite underwhelming. You might call it Afrezza-like sales.
RSO common trades at 18%+ yield, which indicates divi is at high risk. RAS is in the 13% range, high but not ridiculous.
But placebo isn't the standard of care. Doc's will be more interested in how NX-1207 performs against other treatments. It might get approved based on these results, but don't expect much in sales.
Writer had it marked as a "can't miss" investment in the mid $15's. He saw nothing but blue skies in KLIC's sales projections. KLIC is down over 30% since on slowing business. Imagine what a real downturn might do. The old-timers on this board know the business much better than the newbie "professionals".
Until proven otherwise, KLIC remains the canary in the coal mine for the chip equipment biz.
The filing will only be for the subset, not the entire Phase 3 treatment group. Sales may reach $50M/year in the EU by the end of the decade, provided a better treatment option doesn't come along.
Stock is down 50% AH.
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States.
With respect to the United States, after conducting additional safety and efficacy analyses, the company recently met with the FDA. In light of not reaching statistical significance on the protocol-defined primary analysis of overall survival, Sunesis was informed that the Agency did not support a filing and encouraged the company to provide additional clinical evidence to support a future NDA submission.
At 7 AM this morning, EXEL announced that cabo met its primary endpoint for treatment of late stage renal cancer. Stock doubles in premarket. At 8 AM, BMY announces that its Opdivo Phase 3 for late stage renal cancer was stopped early for superior efficacy. A big slug of potential cabo sales just disappeared. So did the EXEL stock price run-up.
It's a competitive world out there.
The housing business is highly cyclical. Construction loans in particular are very high risk. I much prefer the steady life insurance and cemetery businesses, both of which did well last quarter. Wonder if they could bundle them, buy a life insurance policy and get a discount coupon on a cemetery plot. Hoping for a continuation, which includes a reduction in construction loan biz.